Diagnosis and Management of Malignant Pleural Effusion.
- Author:
Hae Seong NAM
1
;
Jeong Seon RYU
Author Information
1. Department of Internal Medicine, School of Medicine, Inha University, Incheon, Korea. jsryu@inha.ac.kr
- Publication Type:Review
- Keywords:
Diagnosis;
Malignancy;
Pleural effusion;
Treatment
- MeSH:
Breast;
Drainage;
Female;
Humans;
Lung;
Lymphoma;
Mesothelioma;
Ovary;
Pleural Effusion;
Pleural Effusion, Malignant;
Pleurodesis;
Recurrence;
Talc
- From:Korean Journal of Medicine
2011;81(2):167-173
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Malignant pleural effusions (MPEs) are an important clinical problem in patients with neoplastic disease. They can occur as the initial presentation of cancer, a delayed complication in patients with previously diagnosed malignancies, or the first manifestation of cancer recurrence after therapy. Common cancer types causing MPEs include lymphomas, mesotheliomas, and carcinomas of the breast, lung, and ovaries. However, almost all tumor types have been reported to cause MPEs. Regardless of the etiology, the median survival from clinical recognition is 4 months. New imaging modalities assist the evaluation of patients with a suspected MPE. However cytologic or tissue confirmation of malignant cells is necessary to establish a diagnosis. Management of an MPE remains palliative. Managements are directed toward removing pleural fluids and when appropriate, performing pleurodesis or initiating long-term drainage to prevent fluid reaccumulation. Talc pleurodesis is still the choice of treatment although concerns about its safety remain. Several factors such as performance status, expected survival, lung re-expansion following pleural fluid drainage and co-morbidities should be considered before the treatment.
